Oregon Health & Science University
Customers
5
2 federal agencies, 3 prime contractors
Suppliers
1
1 federal subcontractor
Largest customer
—
No % disclosed
Named-customer revenue
—
No estimate available
Federal obligations
$1.8M
FY2027 · USAspending.gov
Federal contracts 2
Agencies that awarded contracts to this company, from USAspending.gov. Dollars are obligated amounts as reported, not estimates; $5.8M in the latest fiscal year shown per agency.
| Agency | Obligated | Fiscal year | Awards | Trend | Largest award |
|---|---|---|---|---|---|
| Department of Health and Human Services
National Institutes of Health |
$4.1M | FY 2026 | 13 | $12.0M → $8.5M → $4.1M | 75N93023C00002 |
TO CARRY OUT DEVELOPMENT FOR A DRUG CANDIDATE SMALL MOLECULE INHIBITOR AGAINST CHIKUNGUNYA VIRUS, AN ALPHAVIRUS THAT CAUSES DEBILITATING AND SOMETIMES LIFE-THREATENING DISEASE IN HUMANS. | |||||
| Department of Veterans Affairs
Department of Veterans Affairs |
$1.8M | FY 2027 | 4 | $20.8M → $14.8M → $14.7M → $19.3M → $1.8M | 36C26027N0024 |
SSA INTERVENTIONAL RADIOLOGY PHYSICIAN SERVICES - OPTION PERIOD ONE YEAR 3 POP: 10/1/2026-9/30/2027 648C75035 | |||||
Federal subcontractors 1
Companies this contractor subcontracted work to on federal prime contracts. From USAspending.gov subaward reports; amounts are as reported by the prime contractor, latest report per subaward, $500K+ a year.
| Company | Subawards | Fiscal year | Count | Trend | Largest subaward |
|---|---|---|---|---|---|
| University Of North Carolina AT Chapel Hill | $811.4K | FY 2025 | 1 | 75N93023C00002 | |
DEVELOPMENT OF A NOVEL 2-PYRIMIDONE (SRI-42718) AS A POTENT INHIBITOR OF CHIKUNGYA VIRUS INFECTION AND DISEASE | |||||
Federal subcontracts received 3
Prime contractors that subcontracted federal work to this company. From USAspending.gov subaward reports; amounts are as reported by the prime contractor, latest report per subaward, $500K+ a year.
| Company | Subawards | Fiscal year | Count | Trend | Largest subaward |
|---|---|---|---|---|---|
| Seattle Children's Healthcare System | $8.0M | FY 2025 | 1 | 75N93019C00070 | |
UNDER THIS OPTION WE WILL CONDUCT STUDIES IN RM TO VALIDATE THE EFFICACY OF THE RHCMV/TB VECTOR ORTHOLOG OF THE HUMAN CMV VACCINE CANDIDATE (VIR-1778) CURRENTLY SCHEDULED FOR TESTING IN A PHASE 1 CLINICAL TRIAL. WE WILL ALSO DEVELOP AND TEST RHCMV VECTORS THAT ARE MODIFIED TO REDUCE OR ELIMINATE THE DELETERIOUS IMMUNOREGULATORY EFFECTS OF THE CONTROL RHCMV VECTORS THAT LED TO ACCELERATED TB DISEASE, IN PARTICULAR VECTOR BACKBONE MODIFICATIONS THAT WILL KEEP THE RHCMV/TB VECTOR OUT OF THE LUNG, AS WELL AS OBVIATE ITS ABILITY TO INFECT MONOCYTE/MACROPHAGES, ENDOTHELIAL AND EPITHELIAL CELLS SAND TO PRODUCE IMMUNOREGULATORY VIRAL (V) IL-10 (YEARS 6-7). SUB-ACTIVITY 1: GENERATE A RHCMV/TB (AND RHCMV/CONTROL) VECTOR BASED ON THE VIR-1778 HCMV/TB VECTOR (FL-RHCMV + ∀ RH157.5-∀ RH157.4 + RH107 R MTB-7AG) AND 4 DIFFERENT MODIFIED VERSIONS OF THIS ORTHOLOG VECTOR DESIGNED TO OBVIATE THE DELETERIOUS IMMUNOREGULATION MENTIONED ABOVE. ALL VECTORS WILL BE MADE AS BOTH TB-7AG INSERT EXPRESSION VECTORS (USING THE SAME TB-7AG CASSETTE BEING USED IN VIR 1778), AND AS A CONTROL VECTOR EXPRESSING AN INSERT OF ROUGHLY SIMILAR SIZE EXPRESSING UNRELATED SIV AGS. SUB-ACTIVITY 2: SELECT 2 OF THE 4 BACKBONE DESIGNS FROM SUB-ACTIVITY 1 AND THE VIR-1778 ORTHOLOG VECTOR SET FOR IMMUNOGENICITY AND EFFICACY TESTING IN MONKEYS, COMPARING THE BACKBONES WITH MTB VS. CONTROL AG INSERTS VS. UNVACCINATED CONTROLS. THE FOLLOWING GROUPS WILL BE TESTED USING UP TO A TOTAL OF 56 MONKEYS: €¢ VECTOR A (VIR-1778 ORTHOLOG) AND MATCHING CONTROL AG INSERT VECTOR; 8 MONKEYS EACH €¢ VECTOR B* (MODIFIED VIR-1388 ORTHOLOG VECTOR #1) AND MATCHING CONTROL AG INSERT VECTOR; 7-8 MONKEYS EACH €¢ VECTOR C* (MODIFIED VIR-1388 ORTHOLOG VECTOR #2) AND MATCHING CONTROL AG INSERT; 7-8 MONKEYS EACH, AND €¢ 8 UNVACCINATED CONTROLS SUB-ACTIVITY 3: PERFORM TIMED NECROPSIES AT WEEK 4 OR 5 POST-CHALLENGE AND PERFORM MICROBIOLOGIC AND HISTOPATHOLOGIC/IN SITU ANALYSES TO MEASURE EXTENT OF MTB INFECTION. SUB-ACTIVITY 4: CONDUCT LONGITUDINAL AND END-POINT (NECROPSY) ASSAYS TO MONITOR TRANSCRIPTOMIC PREDICTORS OF VACCINE EFFICACY AND THE DEVELOPMENT AND RESPONSE TO MTB CHALLENGE OF MTB-SPECIFIC CD4+ AND CD8+ T CELL RESPONSES AND INNATE €œTRAINED€Ͽ½ IMMUNITY. VECTOR B AND C TO BE SELECTED FROM VECTORS WITH THE FOLLOWING ADDITIONAL MODIFICATIONS (THAT IS ADDED TO TO THE VIR-1378 ORTHOLOG VECTOR BACKBONE) €¢ SINGLE CYCLE VERSION: + RH108-FKBP €¢ VIL-10 DELETED: + ∀ RH143 €¢ MYELOID, ENDOTHELIAL AND EPITHELIAL TROPISM-RESTRICTED AND VIL-10 DELETED: + ∀ RH143 + MIR126/142/205 (RH108/RH156) €¢ DOUBLE-DELETED AND MYELOID, ENDOTHELIAL AND EPITHELIAL TROPISM-RESTRICTED AND VIL-10 DELETED: + ∀ RH143 + MIR126/142/205 (RH108/RH156) + ∀ RH158-∀ RH161 | |||||
| University Of Pittsburgh - Of The Commonwealth System Of Higher Education | $694.8K | FY 2025 | 1 | W81XWH18F0426 | |
PREHOSPITAL AIRWAY CONTROL TRIAL BASE AWARD | |||||
| Deloitte & Touche LLP | $648.2K | FY 2025 | 1 | 75FCMC24F0066 | |
REGIONAL LEARNING SYSTEM CONTRACT FOR THE CENTER FOR MEDICARE & MEDICAID INNOVATION (CMMI) - BASE YEAR | |||||
Alerts are coming
Get an email when Oregon Health & Science University's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.